4931-00-4

Basic information

• Product Name: 2-hydrazino-4-methylpyridine
• Synonyms: 2-hydrazino-4-methylpyridine;pyridine, 2-hydrazino-4-methyl-;4-Methyl-2-pyridylhydrazine;2-Hydrazinyl-4-Methylpyridine;2-Hydrazino-4-picoline, (4-Methylpyridin-2-yl)hydrazine;(4-Methyl-pyridin-2-yl)-hydrazine;2-hydrazino-4-methylpyridine hydrochloride
• CAS NO: 4931-00-4
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.15576
• Mol File: 4931-00-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 74 °C
• Boiling Point: 88-89 °C(Press: 0.02 Torr)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 9.85±0.70(Predicted)
• CAS DataBase Reference: 2-hydrazino-4-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydrazino-4-methylpyridine(4931-00-4)
• EPA Substance Registry System: 2-hydrazino-4-methylpyridine(4931-00-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 4931-00-4(Hazardous Substances Data)

Usage

General Description

2-hydrazino-4-methylpyridine is a chemical compound with the molecular formula C6H8N4. It is a derivative of pyridine, containing a methyl group and a hydrazine functional group. 2-hydrazino-4-methylpyridine is known for its use in the pharmaceutical and agrochemical industries, where it is utilized as a building block for the synthesis of various biologically active compounds, including potential anticancer and antiviral agents. 2-hydrazino-4-methylpyridine also exhibits antifungal activity, making it a valuable tool in the development of new fungicidal agents. Additionally, it has been studied for its potential use as a corrosion inhibitor in industrial applications. Due to its versatile properties and wide range of potential applications, 2-hydrazino-4-methylpyridine is a compound of interest for ongoing research and development efforts in the fields of medicine, agriculture, and materials science.

Upstream product

• 3678-62-4 2-chloro-4-picoline 
• 108-89-4 picoline 
• 461-87-0 2-fluoro-4-methylpyridine 

Downstream Products

• 5528-57-4 7‐methyl‐2H,3H‐[1,2,4]triazolo[4,3‐a]pyridin‐3‐one 
• 4926-16-3 7-methyl-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine 
• 4919-10-2 7-Methyl-s-triazolo<4,3-a>pyridin 

Relevant articles and documents

Metal free [4+1] and [5+1] annulation reactions to prepare heterocycles using DMF and its derivatives as one-carbon source

1,2,4-Triazolo[3,4-a]pyridines and related heterocycles and substituted triazines were commonly discovered scaffolds in a variety of pharmaceutical and agrochemical agents. Herein, we report a highly efficient and practical method using DMF and its derivative for the [4+1] and [5+1] annulation reactions to prepare these heterocycles. This metal free reaction takes advantages of shelf stable DMF as solvent and carbon donor, imidazole chloride as a catalyst, the mild reaction condition tolerates a broad substrate range and substitutes. The prepared 3-unsubstituted 1,2,4-triazolo[3,4-a]pyridine and derivatives allow further introduction of a variety of functional group1 at 3-position.

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists

Previously disclosed C6 amido and benzimidazole dihydropyrazolopyrimidines were potent and selective blockers of IKur current. Syntheses and SAR for C6 triazolo and imidazo dihydropyrazolopyrimidines series are described. Trifluoromethylcyclohexyl N(1) triazole, compound 51, was identified as a potent and selective Kv1.5 inhibitor with an acceptable PK and liability profile.